Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Atanu Bhattacharjee x
Clear All Modify Search
Open access

Atanu Bhattacharjee, Vijay M. Patil, Vanita Noronha, Amit Joshi and Kumar Prabhash


The best effective dose of a chemotherapy is defined using the maximum tolerated dose (MTD) of toxicity. It is possible that the toxicity of a dose may increase when the dose-response curve is not monotonic. In the case of metronomic chemotherapy (MC) a 1/10th level of MC dose is considered as a targeted dose of therapy and is safer in terms of toxicity levels. The objective of this study is to develop an algorithm based on the dose response model of MC to evaluate the best effective dose based on the molecular target agent. The molecular target agent is defined as the optimal biological dose achieved by the best effective dose, as the lowest dose with the highest rate of safety and efficacy. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose determination, and the second design uses quadratic regression to identify the optimal biological dose. We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies provide a possible way to decide on the best effective dose of MC to be considered in further phases through the finding of the optimal biological dose. The proposed design is assumed, with the threshold value of optimum biological dose (OBD), to detect the best dose of MC. This consistent design with specific dose response models can be recommended for practice.

Open access

Dilip C. Nath, Ramesh K. Vishwakarma and Atanu Bhattacharjee


Methods for dealing with missing data in clinical trials have received increased attention from the regulators and practitioners in the pharmaceutical industry over the last few years. Consideration of missing data in a study is important as they can lead to substantial biases and have an impact on overall statistical power. This problem may be caused by patients dropping before completion of the study. The new guidelines of the International Conference on Harmonization place great emphasis on the importance of carefully choosing primary analysis methods based on clearly formulated assumptions regarding the missingness mechanism. The reason for dropout or withdrawal would be either related to the trial (e.g. adverse event, death, unpleasant study procedures, lack of improvement) or unrelated to the trial (e.g. moving away, unrelated disease). We applied selection models on liver cirrhosis patient data to analyse the treatment efficiency comparing the surgery of liver cirrhosis patients with consenting for participation HFLPC (Human Fatal Liver Progenitor Cells) infusion with surgery alone. It was found that comparison between treatment conditions when missing values are ignored potentially leads to biased conclusions.